-
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
04 Feb 2026 23:29 GMT
… FIGHT DMD trial evaluating oral thromboxane … heart disease medications to manage blood … treatment of constipation;
Sancuso® (granisetron) transdermal, for the prevention of nausea … releases/cumberland-pharmaceuticals-receives-fda-fast-track-designation-for …
-
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
04 Nov 2025 22:17 GMT
… pharmaceutical company, announced today that its product portfolio of FDA … gastric cancer. … treatment of constipation;
Sancuso® (granisetron) transdermal, for the prevention of nausea … chemotherapy, the Sancuso patch slowly and continuously releases the medicine …
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
29 Oct 2025 00:50 GMT
… . Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated … treatment of constipation;
Sancuso® (granisetron) transdermal system, for the prevention of nausea … and vomiting in patients receiving certain types of chemotherapy treatment …
-
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
20 Oct 2025 13:28 GMT
… treatment of constipation;
Sancuso® (granisetron) transdermal, for the prevention of nausea … other cancer and … chemotherapy and radiotherapy induced nausea … fda-approved-product-to-its-commercial-portfolio-302588788.html
SOURCE Cumberland Pharmaceuticals …
-
CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
13 Oct 2025 13:40 GMT
… contact Cumberland Pharmaceuticals Medical Affairs at … have become drug-resistant, … treatment of constipation;
Sancuso® (granisetron) transdermal, for the prevention of nausea … and vomiting in patients receiving certain types of chemotherapy treatment …
-
CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
01 Oct 2025 11:05 GMT
… opioid medications, … Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc … treatment of constipation; Sancuso ® ( granisetron ) transdermal, for the prevention of nausea … and vomiting in patients receiving certain types of chemotherapy treatment …
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
29 Jul 2025 20:43 GMT
… .
Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated … treatment of constipation;
Sancuso® (granisetron) transdermal system, for the prevention of nausea … and vomiting in patients receiving certain types of chemotherapy treatment …
-
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
07 Nov 2024 01:20 GMT
… bring transformative medicines to a … qualified clinical trials and potential … Sancuso® (granisetron) Transdermal delivery system, for the treatment of nausea … pharmaceuticals-receives-fda-orphan-drug-and-rare-pediatric-disease-designations-for-new-treatment …
-
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
13 May 2025 20:32 GMT
… Pharmaceuticals on this important clinical trial … respiratory medicine gatherings … treatment of constipation;
Sancuso® (granisetron) transdermal, for the prevention of nausea … and vomiting in patients receiving certain types of chemotherapy treatment …
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
29 Apr 2025 20:59 GMT
… ;.
Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated … treatment of constipation;
Sancuso® (granisetron) transdermal system, for the prevention of nausea … and vomiting in patients receiving certain types of chemotherapy treatment …
About
© 1995-2026